The Sstl polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats

American Journal of Clinical Nutrition

Volumn 68, Issue 2, 1998, Pages 396-401

  Salas, Joaquín ^b   Jansen, Sergio ^b   López Miranda, José ^b   Ordovás, José M ^b   Castro, Pedro ^b   Marín, Carmen ^b   Ostos, María A ^b   Bravo, María D ^b   Jiménez Perepérez, José ^b   Blanco, Angeles ^b   López Segura, Fernando ^b   Pérez Jiménez, Francisco ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b NONE

Author keywords

APOC3; Apolipoprotein C III; Diet; Genetic polymorphism; Insulin resistance; Men; Monounsaturated fatty acids; Oral glucose tolerance test; S1 allele; S2 allele; SstI

Indexed keywords

APOLIPOPROTEIN C; INSULIN; APOLIPOPROTEIN C3;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; FAT INTAKE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; ORAL GLUCOSE TOLERANCE TEST; BODY MASS; CARBOHYDRATE METABOLISM; GENETICS; GLUCOSE TOLERANCE TEST; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; BODY MASS INDEX; CARBOHYDRATE METABOLISM; DIETARY FATS; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; POLYMORPHISM, GENETIC;

EID: 0031595888     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/68.2.396     Document Type: Article

References (45)

1. Reaven CM. The role of the insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992;41(suppl):16-9.
2. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
3. Felber JP. Significance of the Randle-mechanism in the etiology of Diabetes type II. Horm Metab Res 1990;22(suppl):11-7.
4. Després JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
5. Moller DE, Bjorbaek C, Vidal-Puig A. Candidate genes for insulin resistance. Diabetes Care 1996;19:396-400.
6. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.
7. Ginsberg HN, Le NA, Golberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and A-I. Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
8. Humphries SE. DNA polymorphisms of the apolipoprotein genes. Their use in the investigation of the genetic component of hyperlipidaemia and atherosclerosis. Atherosclerosis 1988;72:89-108.
9. Tybjaer-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries S. Genetic markers in the apo A-I/C-III/A-IV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993;100:157-69.
10. Benlian P, Boileau C, Loux N, et al. Extended haplotypes and linkage disequilibrium between II markers at the apo A1-C3-A4 gene cluster on chromosome 11. Am J Hum Genet 1991;48:903-10.
11. Xu CF, Nanjee MN, Savill J, et al. Variation at the apolipoprotein A-I/C-III/A-IV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian children. Am J Hum Genet 1990;47:429-39.
12. Ordovás JM, Civeira F, Genest J Jr, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Atherosclerosis 1991;87:75-86.
13. Ramakrishnan R, Talmud P, Humphries S, et al. Relationship of apoprotein B and apoprotein C-III polymorphisms with postprandial lipemia. Circulation 1995;92:1-493 (abstr).
14. Rees A, Shoulders CC, Stocks J, Galton DJ, Baralle FE. DNA polymorphism adjacent to the human apoprotein A-I gene: relation to hypertriglyceridemia. Lancet 1983;1:444-6.
15. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A 1993;90:4562-6.
16. Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nikkilä E. DNA polymorphism of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis 1987;66:145-52.
17. Cole SA, Szathmry E, Ferrell RE. Gene and gene-product variation in the apolipoprotein A-I/C-III/A-IV cluster in the Dogrib Indians of the Northwest Territories. Am J Hum Genet 1989;44:835-43.
18. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles. J Clin Invest 1992;90:1889-900.
19. Tas S, Abdella N. Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus: relation to apolipoprotein C-III gene polymorphism. Lancet 1994;343:1194-5.
20. Ferns GA, Stocks J, Ritchie C, Galton DJ. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet 1985;2:300-3.
21. De Lorenzo F, Rubba P, Monticelli A, Cocozza S. Coronary heart disease, echo-Doppler evidence of peripheral arterial disease and polymorphism of apolipoprotein B gene and apo A-I/C-III cluster. Angiology 1993;44:785-90.
22. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148:36-69.
23. Human Nutrition Information Service, US Department of Agriculture. Composition of foods. Washington, DC: US Government Printing Office, 1987. (Agriculture handbook no. 8.)
24. Varela G. Tablas de composición de alimentos. (Food composition tables.) Madrid: Instituto de Nutrición CSIC, 1980 (in Spanish).
25. Association of Official Analytical Chemists. Official methods of analysis. 15th ed. Arlington, VA: Association of Official Analytical Chemists, 1990.
26. Rose HB, Oklander M. Improved procedure for the extraction of lipid from human erythrocytes. J Lipid Res 1965;6:428-31.
27. Allain CC, Poon LS, Chang CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
28. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-82.
29. 2. Clin Chem 1983;29:2026-30.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31. Riepponen P, Marniemi J, Rautaoja T. Inmunoturbidimetric determinations of apolipoproteins A-I and B in serum. Scand J Clin Lab Invest 1987;47:739-44.
32. Ruiz Gutierrez V, Prada JL, Pérez Jiménez F. Determination of fatty acid and triacylglycerol composition of human very-low-density lipoproteins. J Chromatogr 1993;622:117-24.
33. Catt KJ, Traeger GW. Solid-phase radioimmunoassay in antibody coated tube. Science 1967;158:1570-2.
34. Foster DW. Insulin resistance, a secret killer? N Engl J Med 1989;320:733-4.
35. Parker DR, Weiss ST, Troisi R, Cassano PA, Vokonas PS, Landsberg L. Relationship of dietary saturated fatty acids and body habitus to serum insulin concentrations: the Normative Aging Study. Am J Clin Nutr 1993;58:129-36.
36. Storlien LH, Pan DA, Kriketos AD, Baur LA. High fat diet induced insulin resistance. Lessons and implications from animal studies. Ann N Y Acad Sci 1993;683:82-90.
37. Parillo M, Rivellese AA, Ciardullo AV, et al. A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. Metabolism 1992;41:1373-8.
38. Espino A, López MJ, Castro P, et al. Monounsaturated fatty acid enriched diets lower plasma insulin levels and blood pressure in healthy young men. Nutr Metab Cardiovasc Dis 1996;6:147-54.
39. Tas S. Genetic predisposition to coronary heart disease and gene for apolipoprotein C-III. Lancet 1991;337:113-4.
40. Li W, Dammerman M, Smith JD, et al. Common genetic variation in the promoter of the human apo C-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96:2601-5.
41. Steiner G. Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Diabetes Care 1991;14:1077-81.
42. Randle PJ, Garland PB, Hales EA. Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
43. Bjontorp P. Fatty acids, hyperinsulinemia, and insulin resistance: which comes first. Curr Opin Lipidol 1994;5:166-74.
44. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989;149:1514-20.
45. Golay A, Felber JP, Jequier E, DeFronzo RA, Ferrannini E. Metabolic basis of obesity and non-insulin dependent diabetes mellitus. Diabetes Metab Rev 1988;4:727-47.